Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Vertex Pharmaceuticals (VRTX) Stock Price & Analysis
5,210 Followers
VRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$320.01 - $448.40
Previous Close$437.49
Volume1.22M
Average Volume (3M)1.02M
Market Cap
$112.90B
Enterprise Value$103.45B
Total Cash (Recent Filing)$10.17B
Total Debt (Recent Filing)$721.30M
Price to Earnings (P/E)28.4
Beta0.60
Next Earnings
Aug 01, 2024EPS Estimate
$4.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.41
Shares Outstanding258,053,387
10 Day Avg. Volume1,152,017
30 Day Avg. Volume1,021,061
Standard Deviation0.08
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.65
Price to Sales (P/S)41.96
Price to Cash Flow (P/CF)21.20
P/FCF Ratio22.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.16
Enterprise Value/Gross Profit12.02
Enterprise Value/Ebitda27.33
Forecast
1Y Price Target
$457.73Price Target Upside3.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Vertex Pharmaceuticals News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Bulls Say, Bears Say
Bulls Say
Drug Approval PotentialThe recent submission of Vanzacaftor’s triple combination therapy for NDA could lead to approval and higher gross margins for Vertex.
Financial PerformanceVertex reported revenue of $2.69B, surpassing consensus estimates, coupled with a robust non-GAAP EPS, reflecting strong financial health.
Pipeline DevelopmentVertex is expanding its product pipeline, with promising developments such as the resumption of dosing in the VX-880 study and anticipated progress in multiple Phase 3 and Phase 2 trials.
Bears Say
Financial PerformanceInterest income, which contributed to the strong bottom line, is likely to drop off sharply in the second half of the year following the Alpine deal closure.
Future Growth ConcernsIt is currently unclear what the next material growth driver is for Vertex after CF, with premium valuation shares at a P/E multiple above the peer average.
Product LaunchInitial sales of Casgevy may start slower than expected, with revised estimates significantly lower than previous forecasts.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $320.01 and its highest was $448.40 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on May 06, 2024. The company reported $4.76 earnings per share for the quarter, beating the consensus estimate of $4.073 by $0.687.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.17.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,053,380 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.76 in its last earnings report, beating expectations of $4.073. Following the earnings report the stock price went up 1.923%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Bridgewater Associates, LP. It holds Vertex Pharmaceuticals’s shares valued at 54M.
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$457.73 (3.88% Upside)
$457.73 (3.88% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.48%
12-Months-Change
Fundamentals
Return on Equity
24.38%
Trailing 12-Months
Asset Growth
26.05%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VRTX Company Deck
---
VRTX Earnings Call
Q1 2024
0:00 / 0:00
---
VRTX Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
VRTX Stock 12 Month Forecast
Average Price Target
$457.73
▲(3.88% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
30/35 ratings generated profit
1 Year Average Return
+13.63%
assigned a buy rating 7 days ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +13.63% per trade.
---